I am impressed(who cares) with all the fundamental changes since beginning of the year... plus Nasdaq uplisting but the most intriguing change to me is the new perception(rebranding of cdxc) going forward LESS INGREDIENT(PLATFORM) AND MORE PHARMACEUTICAL
ps-valuation would change as rebranding efforts take hold.